Company news
Chimeric Therapeutics Limited (ASX:CHM) news
Every Chimeric Therapeutics Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
CHM ceases enrolment in Phase 1 trial and Company update
August 18, 2026
Chimeric receives $1.62M advance on FY26 R&D tax incentive
July 29, 2026
CHM CDH17 Phase 1 clinical trial update - New DL 3 data
July 15, 2026
Appointment of Financial Adviser for Strategic Review
June 30, 2026
CHM announces positive Phase 1/2 data at ASCO
May 31, 2026
Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
April 21, 2026
Consolidation/Split - CHM
March 18, 2026
Chimeric receives $1.8 M advance on FY26 R&D tax incentive
March 1, 2026
Half Year Report and Appendix 4D 31 December 2025
February 27, 2026
Portfolio streamlined - return of CHM CLTX to City of Hope
February 26, 2026
Funding and EGM update
February 24, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 27, 2026
$8.4 M funding to drive CHM CDH17 and resignation of CMO
December 22, 2025
Trading Halt
December 18, 2025
CDH17 granted FDA Orphan Drug Designation for Gastric Cancer
December 7, 2025
CHIMERIC RECEIVES $4.5M R&D TAX INCENTIVE
November 23, 2025
75% disease control observed in CHM CDH17 trial
November 12, 2025
CHM CORE NK Combination Phase 1b trial update
November 12, 2025
Pause in Trading
November 12, 2025
Response to ASX Query Letter
November 6, 2025
Additional complete responses in CHM CORE-NK Phase 1b trial
October 2, 2025
Disease control and tumour shrinkage observed in CHM CDH17
September 28, 2025
Appendix 4E and Annual Report
August 29, 2025
CHM CDH17 Clinical Trial Update
August 3, 2025
Chimeric receives $2.5 M advance on FY25 R&D tax incentive
June 10, 2025
CHM CDH17 receives FDA Fast Track
June 4, 2025
CHM CDH17 ADVANCES TO DOSE LEVEL 2
May 20, 2025
$6.6 million Placement to advance clinical trial pipeline
May 20, 2025
ADVENT-AML Phase 1B clinical trial update
May 15, 2025
Completion of Entitlement Offer
April 24, 2025
Prospectus
March 17, 2025
Entitlement Offer to raise approximately $3.2 million
March 17, 2025
Reinstatement to Quotation
March 4, 2025
Chimeric announces intention to undertake Entitlement Offer
March 4, 2025
Suspension from Quotation
March 2, 2025
Half Year Report and Appendix 4D 31 December 2024
February 28, 2025
$4.0m Non-Dilutionary Funding
February 27, 2025
Phase 1B CHM CORE-NK trial advances to newly diagnosed AML
December 15, 2024
Chimeric receives $4.17m R&D tax incentive
November 27, 2024
AGM Presentation and CEO Appointment
November 11, 2024
Reinstatement to Official Quotation
October 21, 2024
$5 million Placement to progress CHM CDH17 trial
October 21, 2024
AML patient achieves Complete Response in CHM CORE-NK trial
October 6, 2024
Appendix 4E and Preliminary Final Report
August 30, 2024
First patient dosed in Phase 1/2 trial of CHM CDH17
August 28, 2024
First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
July 22, 2024
Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
June 4, 2024
Chimeric opens CHM CDH17 Phase 1/2 trial
May 22, 2024
CHM CDH17 Phase 1/2 clinical trial approved for initiation
May 19, 2024
Resignation of CEO and Managing Director
May 1, 2024